HYALURONATE VISCOSUPPLEMENTATION FOR TRAPEZIOMETACARPAL OSTEOARTHRITIS

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们提出，与安慰剂（生理盐水）相比，将EUFLEXXA？关节内注射到基底关节（拇指掌侧关节）将显著缓解疼痛并恢复功能，用于治疗基底关节骨关节炎。 EUFLEXXA是1%的透明质酸钠，经FDA批准并在临床上用于治疗膝关节骨关节炎。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose that intraarticular injection of EUFLEXXA¿ into the basal joint (trapeziometacarpal joint of the thumb) will provide significant pain relief and restoration of function as compared to placebo (normal saline) for osteoarthritis of the basal joint. EUFLEXXA is 1% sodium hyaluronate and is FDA approved and in clinical use for the treatment of knee joint osteoarthritis.